He currently manages a fund that invests in healthcare and biotechnology companies. Before moving to Anna's current city of Boston, MA, Anna lived in Woodstock VT and Carlisle MA. CB Rank (Investor) 53,342 Primary Job Title Portfolio Manager and Managing Director Primary Organization RA Capital Management Location Boston, Massachusetts, United States Regions Greater Boston Area, East Coast, New England Gender Male Investor Type Investment Partner LinkedIn View on LinkedIn Dr. Kolchinksy's hedge fund held 9.7 million Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) shares by the end of Q3 of 2021. hope that what we do with the inn will come to reflect the spirit of this wonderful community. Let us know who we should consider our main ask is that you make the nominations personal. In addition, they want, Coming from diverse backgrounds and interests, the foursome. Peter Kolchinsky usually trades in February, with the busiest year in 2023. But there was a new treatment he could try: a targeted radiotherapy called Pluvicto if he could get it in time. Peter Kolchinsky owns about 2,805,045 units of Dyne Therapeutics, Inc. Peter Kolchinsky - Insider Trading Tracker . Recently at Dyne Therapeutics, Inc, Peter Kolchinsky has sold an estimated value of $0 worth. "And another thread that speaks to need for insurance reform. Covid-19. In the companys CLEAR study of nearly 14,000 patients, Esperions drug Nexletol cut the combined risk of heart attack, stroke, cardiovascular death or the need for coronary revascularization by 13%, compared with placebo. and bought an estimated value of $190.71M worth of shares. RA Capital Management, L.P. is the investment manager of RA Capital Healthcare Fund, L.P. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. the community will feel welcome. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. She received her bachelors degree from Furman University in South Carolina in Philosophy and Asian Studies. Peter served on the Board of Global Science and Technology for the National Academy of Sciences and writes about the biotech social contract. Peter Kolchinsky, PhD '01, is a founder, Portfolio Manager, and Managing Director at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life sciences. Track performance, allocation, dividends, and risks, Annotate, download XLSX & look up similar tables, Filter, compare, and track coins & tokens. Baeder explains below not only whats coming for AAM and its member generic drug companies, but also her thoughts on the Inflation Reduction Act and the new five-year FDA user fee deal. The biopharmaceutical industry will be able to make a Covid-19 vaccineprobably a few of themusing various existing vaccine technologies. So lets meet our newest neighbors in Woodstock. December 22nd, 2014. . Peter Kolchinsky. Boston, MA. He studied philosophy at Oregon State University and then earned a law degree from the University of Oklahoma. In the interim, they plan to invite local folks in to see the changes, try out some wines, and make new friends. GuruFocus.com is not operated by a broker or a dealer. Managing Partner | RA Capital Management Peter is a founder and Managing Partner at RA Capital Management, active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. The name for the inn was Annas inspiration; The Blue Horse Inn speaks both to her German heritage and her love of art and horses. Peter Kolchinsky owns about 1,311,247 units of Mineralys. The estimated Net Worth of Peter Kolchinsky is at least $96 million dollars as of 23 June 2020. She received her bachelors degree from Furman University in South Carolina in Philosophy and Asian Studies. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company's proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Peter Kolchinsky and Raj Shah raise a $300M fund devoted to biotech startups John Carroll Editor & Founder Josh Resnick RA Capital Peter Kolchinsky and Raj Shah have another $300. In the interim, they plan to invite, Were not in a rush, Anna explained, and want to take some time to get to know the. Peter Kolchinsky owns about 2,805,045 units of Dyne Therapeutics, Inc common stock. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. $5M . Above is the net worth, insider trading, and ownership report for Kolchinsky Peter. With a few impressions we look back on this event and would like to thank very much all companies who made the North The two announced Monday morning that theyve put together their first pure-play venture fund at RA Capital Management, which has been known to bet on just about every angle in healthcare investing from rounds to follow-on investments at public companies. Hedge Fund Net Worth $4.93B Peter Kolchinsky manages more assets than 43% of other Hedge Fund Managers Average Return +0.32% Since Last Filing Last 12 Months 3 Years (Annualized) Portfolio Breakdown by Sector Portfolio Breakdown 97.31% Healthcare 1.12% Services 0.78% Technology 0.51% Financial RA Capital Management Portfolio Activity Company Name This is where youll find the low down on whats happening in and around the BHI. Most recently he bought 4,000,000 units of WVE stock worth $80,000,000 on 23 June 2020. The largest trade he's ever made was buying 4,545,455 units of Wave Life Sciences stock on 11 December 2018 worth over $50,000,005. Your email address will not be published. But many people worry that Covid-19 will mutate and . In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Carl Ashley Morris who sold, In the last 5 years, insiders at Solid Biosciences Inc have sold an estimated value of, Mailing address is 200 Berkeley Street 18th Floor Boston MA 02116 MA. . Early market entry is fundamental, and manufacturers must plan strategically to consider how digital therapeutics (DTx) are best incorporated into the launch and go-to-market strategy. Bens got me beat so far by three perch and a bass and Im trying to catch up. . The estimated Net Worth of Peter Kolchinsky is at least $96.3 Million dollars as of 23 June 2020. In addition, he makes $151,598 as Independent Director at Wave Life Sciences. Arab Health 2023? Peter Kolchinsky is 43, he's been the Independent Director of Wave Life Sciences since 2015. On average, Rajeev trades about 455,121 units every 31 days since 2016. How do you see re-infections? Come and visit me at the Pacific Water Conference, booth 520! The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. Couple Number One: Peter and Anna Kolchinsky: Peter Kolchinsky grew up in the Boston area, studied biology at Cornell, and has a PhD in Virology from Harvard. In total, Peter Kolchinsky has made about 5 transactions over a year of their time at Solid Biosciences Inc. Fundamental company data provided by Morningstar, updated daily. One hopeful voice is biotech investor Peter Kolchinsky, the founder of RA Capital Management. The estimated Net Worth of Peter Kolchinsky is at least $105 Milion dollars as of 23 June 2020. Forbes and business insiders have done a recent study and say that Peter Kolchinsky net worth is more than a couple of million dollars. On average, Wave Life Sciences executives and independent directors trade stock every 39 days with the average trade being worth of $949,631. Peter Kolchinsky graduated from Harvard with a Ph.D. in virology in 2001. This investment adviser does not provide advice to individual investors. The singer-songwriter and actress is the latest celebrity addition to Merz Aesthetics Beauty on Your Terms campaign for Botox rival Xeomin. New to Endpoints? If you're already an Endpoints subscriber, enter your email below for a 2004-2023 GuruFocus.com, LLC. The Kolchinskys came. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. Nominations are now open for a special report that will highlight the contributions of LGBTQ+ biopharma leaders. Eric Lefkofsky, Tempus founder and CEO (Photo by Michael Kovac/Getty Images), Christina Aguilera joins Merz Aesthetics' 'Beauty on Your Terms' campaign for Botox rival Xeomin, Hemolytic Anemia Sales Specialist, Rare Genetic Diseases, Peter Kolchinsky and Raj Shah raise a $300M fund devoted to biotech startups, Digital therapeutics: The key to maximizing the potential of medicinal assets, What latest wave of layoffs means for biotech; Radiotherapy shortage; Delivering on mRNA's promises; and more, Harder to find homes: Latest wave of biotech layoffs could test the industry, Esperion unveils long-awaited data on cholesterol pill's ability to cut cardiovascular risk, Tempus founders build a drug discovery startup, Pathos AI, with $40M in sight, A radioactive prostate cancer therapy is a last lifeline for patients. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. Unlock this article along with other benefits by subscribing to one of our paid plans. The URI to TrackBack this entry is: https://bluehorseinnvermont.wordpress.com/2010/03/14/the-blue-horse-six/trackback/. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. Jonathan McNeill who sold 10,000 units worth The malignant cells permeated his bones, kidney, lungs and liver, and in December, his oncologist told him there was no point in continuing chemotherapy treatment. one-time use only and expires after 24 hours. In the last 16 years, insiders at Dyne Therapeutics, Inc have sold an estimated value of $1.64B Peter Kolchinsky owns about 1,311,247 units of Mineralys Therapeutics, Inc common stock. May 5, 2003 Like all mothers, Evelina Kolchinsky wanted her son, Peter, to adjust to school and do well. There are also venture partner and executive-in-residence programs to build up the bench. These were worth $145 million and represented 2% of its portfolio. Refer a Friend and Earn One Month of Free Membership. Peter Kolchinsky's largest purchase order was 2,206,685 units , worth over The higher rates are proposed to kick in on April 1. Insider trading is most common in June, with the busiest year in 2022. 2004-2023 GuruFocus.com, LLC. Dr. Peter Kolchinsky Ph.D. serves as Independent Director of the Company. Harvard Divinity School and began doctoral work in Buddhist studies at the University of California, Berkeley. These things have helped him get to where he is now one of the richest people on Earth. Its a longstanding agreement between the government and industry to keep medicines affordable for the National Health Service (NHS). Anna and Keri hope their husbands dont electrocute themselves in the process. Anna is excited about introducing her dressage horse Jurist to the local network of trails. This investment adviser does not provide advice to individual investors. While high-priced branded drugs make up only 11% of all prescriptions, they are the source of most pharmaceutical revenue ($237 billion in 2015). Listed on the paperwork are Tempus CEO Eric Lefkofsky and operating chief Ryan Fukushima, who is described as CEO of Pathos. The group has been building an incubator with 19 projects and two startups to their credit. magic link that lets you log in quickly without using a password. $20M on February 16, 2023. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Peter Kolchinsky, Ph.D. is a biotechnology investor and a scientist. He serves as a member of the board of directors of a number of private companies. According to world-renowned virologist Peter Kolchinsky, the SARS-CoV-2 virus is nothing short of an "evil genius". It was written by our very kind neighbor, Hasse K. Halley. These two energetic couples are living their dream with energy, imagination, creativity and a whole lot of savvy business sense. In a 2018 article, Eric Bender argued that cancer drugs aren't worth the price we pay for them and recommended legislative measures be taken to align prices with the values drugs provide. But, as it often does, chance overrode plan, and they both fell in love with the property on the first visit. In this conversation. The current estimated net worth of Mineralys Therapeutics, Inc's Director, Peter Kolchinsky, is estimated to be about $2.7B . The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Refer a Friend and Earn One Month of Free Membership. and Peter Kolchinsky, Director Shes currently earning her PhD in European History at Boston College. Unlock this story instantly and join 161,900+ biopharma pros reading Endpoints daily and it's free. Your email address will not be published. Welcome to the official Blue Horse Inn blog! UCLA CTSI | Accelerating Discoveries Toward Better Health | Main In the years Mineralys Therapeutics, Inc was active, insiders at Mineralys Therapeutics, Inc have bought an estimated value of $0 worth of shares. Keri is currently the Chair of the Religious Studies department at St. Pauls School for Girls in Baltimore, Maryland. Past performance is a poor indicator of future performance. Dr. Kolchinsky's firm held 7.3 million Ascendis Pharma A/S (NASDAQ:ASND) shares in Q3, which were worth $1.17 billion and made up for 16.31% of its portfolio. Peter Kolchinsky owns over 4,000,000 units of Wave Life Sciences stock worth over $38,029,167 and over the last 9 years he sold WVE stock worth over $58,095,632. He holds a BA from Cornell University and a PhD in Virology from Harvard University. I am on Oahu until Friday, so please feel free to also contact me directly in order to discuss His wife, Nora Flor, said she and her sister made calls to at least 30 centers across the US looking for the drug. This . (LogOut/ The campaign launched last year, targeting people in their 20s and 30s, Merz Aesthetics North America president Patrick Urban told Endpoints News at the time. But there was a lot of adjusting to do, for everyone in the family. October 20, 2021The vaccine business has long been a quiet and profitable game of kings. Endpoints News Top biotech investor Peter Kolchinsky tees up a new SPAC 3 days after a $300M raise for radiopharmaceuticals play News Dec 9, 2020 Endpoints News RA Capital backs Oxford spinout PepGen with a $45M Series A, seeking to treat Duchenne and other similar diseases She received a Masters degree in TV production at Boston University and worked in film production in Berlin for several years before returning to Boston, where she met Peter. Past performance is a poor indicator of future performance. After serving in the US Air Force JAG Corps, Ben, at a private law firm and in Massachusetts, He currently works with the State and Local Government Practice Group of. Enjoy a 7-Day Free Trial Thru Mar 12, 2023! The information on this site is in no way guaranteed for completeness, accuracy or in any other way. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in Massachusetts with his historian/equestrian wife, strong-willed children, and RA Capital is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are . As the Independent Director of Wave Life Sciences, the total compensation of Peter Kolchinsky at Wave Life Sciences is $151,598. A quarters-long flurry of layoffs has caused thousands of workers in life sciences to go hunting for their next position sooner than expected, and the latest wave could make it more difficult to get new offers in hand in short order. Peter is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools and serves on the boards of publicly- and privately-held life science companies. Wishing you all the best of luck in your new endeavor. In support of his arguments, he shared insights from government and industry professionals and cited facts and figures on the trajectory of the drug market. The drug industry stands accused of charging too much. The fund was seeded by Vertex Pharma co-founder Rich Aldrich, who invested $4 million at . The current estimated net worth of Solid Biosciences Inc's Director, Peter Kolchinsky, is estimated to be about $2.7B . The Voluntary Scheme for Branded Medicines Pricing and Access is the second option, and typically has lower rates and is negotiated between the government and pharmas. The estimated net worth of Peter Kolchinsky is at least $1.2 Billion dollars as of 2023-02-17. This slide deck contains a powerful visual illustration of the biotech industry's race to find a cure for Hepatitis C. Run through the slide deck quickly to appreciate the sheer level of hustle that won the world a cure, and then more slowly to appreciate every move in the chess game of mergers & acquisitions. The current estimated net worth of Dyne Therapeutics, Inc's Peter Kolchinsky is estimated to be about $2.7B . Dr. Kolchinsky earned his Ph.D. in virology from Harvard University and earned his bachelors degree in Biology from Cornell University. Momentum Activist Targets Dividend Yield Microcap with Revenue NCAV Screen Net Net Working Capital Negative Enterprise Value Piotroski Score ROIC Screen Short Volume Ratio High . Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Endpoints News connected with the new chair of the generic industrys Association for Accessible Medicines, Christine Baeder, who is also Tevas COO, via video conference on Friday. More than 100 drug developers thinned their organization charts last year. If you are considering starting your own biotech company, you will appreciate the wealth of practical information packed into The Entrepreneur's Guide to a Biotech Startup. Anna maintains relationships with many people -- family . Quality, Value, Ownership Undervalued - Ebit/EV + B/M Blend Quality, Value, Momentum Activist Targets Dividend Yield Microcap with Revenue NCAV Screen Net Net Working Capital Negative Enterprise Value Piotroski Score ROIC Screen Short Volume Ratio High Insider Selling High Insider Buying January 3, 2023 Feb 10th, Ed. This free 100-page eBook is based on personal interviews with entrepreneurs, investors, attorneys, and other professionals . The most active insiders traders include Capital Management, L.P.Ra , Capital Management, Llc Kol und Peter Kolchinsky. Hbm Healthcare Investments Cayman Ltd who bought, In the years Mineralys Therapeutics, Inc was active, insiders at Mineralys Therapeutics, Inc have bought an estimated value of, Mailing address is 200 Berkeley Street 18th Floor Boston MA 02116 MA. Peter is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research . as vibrant from the outside as it is on the inside. This new fund of theirs arrives well into a go-go era of new startup financing, with a particular focus on building new biotechs. You can see the complete history of Peter Kolchinsky stock trades at the bottom of the page. In 2020, Novavax transformed from a $150 million biotech to an $8 billion vaccine developer. Peter Kolchinsky usually trades in December, with the busiest year in 2022. On average, Peter trades about 366,737 units every 19 days since 2014. Hard work has helped him rise to the top. Industry is going to have to give "a pound of flesh," Kolchinsky argued, and he's explicit on the business practices biopharma must abandon to get a fair system that still rewards innovation. . Peter Kolchinsky Net Worth The estimated Net Worth of Peter Kolchinsky is at least Wave Life Sciences stock worth over $36,046,604 and over the last 8 years he sold WVE stock worth over $58,095,632. Kolchinsky Peter Net Worth 2022 and insider trades. Mineralys Therapeutics, Inc's most recent insider trade came on February 16, 2023 by Peter Kolchinsky is a biotechnology investor and a scientist. Peter Kolchinsky / Published in City Journal / February 24, 2020 "Some health economists, such as those at the Institute for Clinical and Economic Review (ICER), believe that they can tell us the right price to pay for each new medicine that the FDA approves. Come and visit me at the Pacific Water Conference, booth 520! The largest trade he's ever made was buying 6,337,135 units of Kala Pharmaceuticals Inc stock on 13 March 2020 worth over $49,999,995. (LogOut/ By India Today Web Desk: With more than 22 lakh people infected, more than 1.5 lakh dead of the novel coronavirus, health experts all over the world are scrambling to understand just how did this one virus get so potent.. Social image: Peter Kolchinsky and Raj Shah, RA Capital Management, Digital therapeutics support increased access to safe and effective therapies, providing an untapped opportunity for biopharmaceutical companies to maximize the value of medicinal assets and drive differentiation Please note this link is one-time use only and is valid for only 24 hours. Peter Kolchinsky is a founder, Portfolio Manager, and Managing Director at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and. This ground-breaking new book, The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines (January 20, 2020), by Peter Kolchinsky, PhD, examines the healthcare landscape through the lens of the biotech social contract with America - the implicit agreement between the biopharmaceutical industry and American society - including the government's role in inventing . . Add it to the rest of the money and their private deal capacity jumps to $1 billion, with $2.5 billion under management. In the last year at Solid Biosciences Inc, Peter Kolchinsky has sold an estimated value of $0 worth. Shes currently earning her PhD in European History at Boston.